Glenmark Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Glenmark Pharmaceuticals Limited generated cash of -$2,654,440,000, which is less than the previous year. Cash used in financing activities reached the amount of -$39,061,270,000 last year. Net change in cash is therefore $2,152,440,000.
Cash Flow
| 2010 | 3.52B | -3.86B | 700.48M |
|---|---|---|---|
| 2011 | 9.30B | -3.66B | -4.35B |
| 2012 | 8.04B | -2.77B | -3.61B |
| 2016 | 3.44B | -8.80B | 6.98B |
| 2018 | 16.48B | -10.13B | -4.68B |
| 2020 | 13.92B | -7.83B | -4.44B |
| 2021 | 11.31B | -6.75B | -4.41B |
| 2023 | 6.25B | -5.28B | -774.56M |
| 2024 | -2.65B | 45.43B | -39.06B |
GLENMARK.NS Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.43B | 14.10B | 11.10B | 9.36B | 10.56B | 7.63B | 1.94B | 1.03B | 714.82M |
Operating activities | |||||||||
Net income | -15.01B | 8.68B | 13.82B | 10.96B | 10.66B | 10.04B | 4.64B | 4.57B | 3.31B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 6.30B | 6.11B | 4.43B | 4.17B | 3.54B | 2.69B | 978.28M | 946.78M | 1.20B |
Stock-based compensation expense | 49.62M | 67.74M | 79.39M | 30.84M | 90.64M | 0 | 63.98M | 82.71M | 0 |
| Deferred income tax benefit | 49.62M | 67.74M | 79.39M | 30.84M | 90.64M | 0 | 63.98M | 82.71M | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 9.69B | -8.48B | -1.17B | -2.92B | 1.03B | 994.23M | 0 | 0 | 0 |
Inventories | -5.13B | -3.75B | -1.33B | 972.56M | 1.35B | -4.33B | 0 | 0 | -782.33M |
Accounts payable | -7.34B | 1.66B | 1.60B | 1.52B | 2.00B | -251.45M | 0 | 0 | 0 |
Cash generated by operating activities | -2.65B | 6.25B | 11.31B | 13.92B | 16.48B | 3.44B | 8.04B | 9.30B | 3.52B |
Investing activities | |||||||||
Purchases Of Investments | 0 | -60.08M | -29.08M | -1.61B | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -8.98B | -6.07B | -7.74B | -9.31B | -10.44B | -8.90B | -2.85B | -4.01B | -3.95B |
Acquisitions Net | 54.49B | 803.47M | 994.33M | 1.56B | 219.16M | 16.21M | 0 | 0 | 0 |
Cash generated by investing activities | 45.43B | -5.28B | -6.75B | -7.83B | -10.13B | -8.80B | -2.77B | -3.66B | -3.86B |
Financing activities | |||||||||
Common Stock Issued | 12M | 0 | 0 | 0 | 0 | 9.35B | 35.56M | 40.86M | 4.14B |
Payments for dividends | -1.17B | -1.36B | -704.47M | -685.54M | -678.82M | -678.53M | -126.09M | -125.82M | -117.99M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -327M | -232.25M | 0 |
Repayments of term debt | -31.68B | 4.77B | -17.10B | -1.97B | -2.89B | 109.76M | -8.08B | -10.92B | -5.25B |
Cash used in financing activities | -39.06B | -774.56M | -4.41B | -4.44B | -4.68B | 6.98B | -3.61B | -4.35B | 700.48M |
Net Change In Cash | 2.15B | 325M | 278.2M | 1.73B | 1.76B | 933.86M | 1.25B | 912.89M | 355.37M |
Cash at end of period | 16.58B | 14.43B | 11.38B | 11.10B | 12.33B | 8.57B | 3.20B | 1.94B | 1.07B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |